Clinical trials: Non Organic Psychosis
Postpartum Psychosis
Effects Zulresso on Postpartum Psychosis
This is an open-label, proof of concept trial to investigate the efficacy, safety and tolerability of Zulresso (brexanolone) administered to adult female subjects diagnosed with postpartum psychosis.
- Trial name
- NCT05314153
- Testing
- Brexanolone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of North Carolina, Chapel Hill
Psychotic Disorders, Psychosis
Semantic and Syntactic Computerized Analysis of Free Speech
Subtle speech disorganization could be predictive of a transition to schizophrenia of ultra-high-risk patients. The aim of our longitudinal multicenter cohort study is to identify specific linguistic markers of the psychotic…
- Conditions
- Psychotic Disorders, Psychosis, Schizophrenia and Related Disorders, Schizophrenia Prodromal
- Trial name
- ASESID (NCT03525054)
- Where
- 3 sites in France
- Volunteers
- 215 people
- Sponsor
- University Hospital, Brest
Dementia, Alzheimer Disease
Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of risperidone compared with placebo in the treatment of psychotic symptoms in patients with Alzheimer's disease
- Conditions
- Dementia, Alzheimer Disease, Mental Disorders
- Trial name
- NCT00034762
- Testing
- risperidone
- Volunteers
- 473 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Psychosis
An Acceptability Study of Unflavored Asenapine Versus Raspberry Flavored Asenapine in Stable Patients With a Psychotic Disorder (P07010)(COMPLETED)
This trial was a randomized trial to determine a patient's acceptability of unflavored antipsychotic medication compared to raspberry flavored antipsychotic medication.
- Trial name
- NCT00878462
- Testing
- Asenapine WHITE raspberry flavor (Treatment A), Asenapine RED raspberry flavor (Treatment B), Asenapine WHITE UNFLAVORED (Treatment C)
- Volunteers
- 174 people
- Sponsor
- Organon and Co
Alzheimer Disease, Psychotic Disorders
Antipsychotic Discontinuation in Alzheimer's Disease
In patients with Alzheimer's disease (AD) who respond to antipsychotic treatment of psychosis and/or agitation/aggression, the relapse risk after discontinuation is not established.
- Conditions
- Alzheimer Disease, Psychotic Disorders, Agitation, Aggression
- Trial name
- ADAD (NCT00417482)
- Testing
- risperidone
- Where
- 7 sites in United States
- Volunteers
- 180 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia Spectrum Disorders, Cannabis Use
Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis
A large proportion of people with a schizophrenia-spectrum disorder, especially in the early stages of the disease, regularly consume cannabis.
- Trial name
- NCT03883360
- Testing
- Cannabidiol (CBD)
- Where
- 3 sites in United States
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Schizophreniform Disorders
Individual Placement and Support and/or Cognitive Remediation Therapy Added to TAU in Patients With Early Schizophrenia
This study aims to test the hypothesis that addition of Individual Placement and Support (IPS) and/or Cognitive Remediation Therapy (CRT) in addition to treatment as usual in patients with early psychosis will be feasible and…
- Conditions
- Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorder, Psychosis
- Trial name
- NCT03974620
- Testing
- Individual Placement and Support, Cognitive Remediation Therapy
- Volunteers
- 120 people
- Sponsor
- Pakistan Institute of Living and Learning
Bipolar Disorder, Schizoaffective Disorder
Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
Aim: In a population of first episode manic patients with psychotic features, we want to compare the side effect profile, the degree of adherence and the subjective well being, as well as the efficacy of two treatments: The…
- Trial name
- NCT00202293
- Testing
- Olanzapine, Lithium, Chlorpromazine
- Where
- Australia
- Volunteers
- 83 people
- Sponsor
- Melbourne Health
Schizophrenia, Schizophreniform Disorder
Integrated Metacognitive Therapy in First Episode Psychosis
Insight, or lack of illness awareness, is a prominent and pressing clinical concern in the treatment and recovery of patients with psychotic disorders.
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- IMT (NCT02131116)
- Testing
- Integrated Metacognitive Therapy, Treatment as Usual
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Indiana University
Psychosis Associated With Alzheimer's Disease
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease.
- Trial name
- NCT05511363
- Testing
- KarXT
- Where
- 129 sites in United States, Bulgaria and 11 more
- Volunteers
- 410 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Cognitive Impairment, Psychosis
Action-based Cognitive Remediation for First Episode Psychosis
Cognitive impairments are a core and enduring feature of first-episode psychosis and schizophrenia, and are associated with significant functional impairment.
- Trial name
- NCT03814122
- Testing
- Action-based cognitive remediation, Waitlist Control Group
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- University of Manitoba
Schizophrenia, Schizoaffective Disorder
Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects
The purpose of this study is to determine if zonisamide SR will prevent weight gain in schizophrenic subjects who take olanzapine (Zyprexa)
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00734435
- Testing
- zonisamide SR plus olanzapine
- Where
- 9 sites in United States
- Volunteers
- 26 people
- Sponsor
- Orexigen Therapeutics, Inc
Clinical High Risk for Psychosis (CHR)
French Validation of Schizophrenia Proneness Instrument- Child Youth
The clinical concept of a at risk mental state of developing psychosis is based on the identification of attenuated psychotic symptoms during the prodromal phase of psychoses (Schmidt et al., 2015).
- Trial name
- SPI-CY-Fr (NCT06649552)
- Testing
- Psychiatric and psychological diagnostic tests
- Where
- 3 sites in France
- Volunteers
- 52 people
- Sponsor
- Centre Psychothérapique de Nancy
Affective Disorder, Psychosis
Value of Gym-based Exercise Training for Young Adults Receiving Antipsychotic Medication: The Vega Trial
This is a multicentre, pragmatic, randomised controlled trial to estimate the effect of a 4-month gym-based exercise training program on 1) patient-rated personal recovery (primary outcome), 2) Health-related quality of life…
- Trial name
- Vega (NCT05461885)
- Testing
- Supervised exercise
- Where
- 4 sites in Denmark
- Volunteers
- 226 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Psychosis, Sleep
Melatonin Effects on Sleep and Circadian Rhythm in Youth and Young Adults With At-risk Symptoms
Randomized control trial assessing supplemental melatonin for youth with at-risk or psychotic symptoms.
- Trial name
- NCT03826563
- Testing
- oral melatonin tablets (NatureMade brand)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Children's Hospital of Philadelphia
Agitation
Treating Acutely Agitated Patients With Asenapine Sublingual Tablets
Our proposal is to administer asenapine to patients who are clinically agitated and in need of immediate intervention. At present there are no controlled studies that we know of that explores the use of asenapine for this…
- Trial name
- NCT01400113
- Testing
- Asenapine
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Unity Health Toronto
Psychosis, Schizophrenia
Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia
A study of children and adolescents (current N=100) with very early onset by age 12 (COS) of DSM-III-R defined schizophrenia with (97-M-0126) is examining the clinical, neurobiological, early neurodevelopmental, genetic, and…
- Conditions
- Psychosis, Schizophrenia, Genetic Structure, Childhood Onset Psychotic Disorders
- Trial name
- NCT00001198
- Where
- United States
- Volunteers
- 1,556 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Psychosis
Psychosis Associated With Methylphenidate in Children and Adolescents
perform a study in VigiBase® to assess if methylphenidate was associated with an over-reporting of psychosis including hallucinations in children and adolescents and to characterize those psychosis.
- Trial name
- NCT06518330
- Testing
- Intake of Methylphenidate
- Where
- France
- Volunteers
- 46,233 people
- Sponsor
- University Hospital, Caen
Sleep Initiation and Maintenance Disorders
A Study of FK199B to Compare Efficacy With Zolpidem by Polysomnography in Patients With Insomnia
This study is to investigate the efficacy and safety of FK199B (Zolpidem MR Tablet) by polysomnography in patients with insomnia, excluding patients with schizophrenia or manic-depressive psychosis.
- Trial name
- NCT00999219
- Testing
- FK199B, Zolpidem
- Where
- 7 sites in Japan
- Volunteers
- 55 people
- Sponsor
- Astellas Pharma Inc
Schizophrenia, Schizoaffective Disorder
Improving Care and Reducing Cost Study
The goal of the Improving Care and Reducing Cost (ICRC) Program, is to improve disease management and the overall process of care in treating the chronic illness schizophrenia in order to reduce ER visits and hospital days while…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychosis NOS
- Trial name
- ICRC (NCT02364544)
- Testing
- Relapse Prevention Plan, Daily Support Website, Computer CBT for voices and paranoia
- Where
- 8 sites in United States
- Volunteers
- 461 people
- Sponsor
- Northwell Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.